Guizhou Yibai Pharmaceutical Co Ltd (600594) — Cash Flow-to-Debt Ratio
Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.28 Million could theoretically repay 0% of its total liabilities (CN¥1.32 Billion) in one year. Check Guizhou Yibai Pharmaceutical Co Ltd (600594) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guizhou Yibai Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Guizhou Yibai Pharmaceutical Co Ltd across 24 annual periods. Also explore Guizhou Yibai Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Guizhou Yibai Pharmaceutical Co Ltd (2002–2025)
Year-by-year debt coverage analysis for Guizhou Yibai Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Guizhou Yibai Pharmaceutical Co Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥256.71 Million | CN¥1.17 Billion | ▲ +276.8% |
| 2024 | 0.06x | CN¥86.87 Million | CN¥1.49 Billion | ▼ -75.7% |
| 2023 | 0.24x | CN¥377.61 Million | CN¥1.58 Billion | ▲ +16.1% |
| 2022 | 0.21x | CN¥345.30 Million | CN¥1.68 Billion | ▼ -66.8% |
| 2021 | 0.62x | CN¥934.21 Million | CN¥1.51 Billion | ▲ +198.4% |
| 2020 | 0.21x | CN¥366.66 Million | CN¥1.76 Billion | ▲ +8.6% |
| 2019 | 0.19x | CN¥362.71 Million | CN¥1.89 Billion | ▲ +129.1% |
| 2018 | 0.08x | CN¥214.30 Million | CN¥2.56 Billion | ▼ -68.7% |
| 2017 | 0.27x | CN¥681.78 Million | CN¥2.55 Billion | ▲ +68.1% |
| 2016 | 0.16x | CN¥380.62 Million | CN¥2.40 Billion | ▼ -43.6% |
| 2015 | 0.28x | CN¥573.68 Million | CN¥2.04 Billion | ▲ +7.7% |
| 2014 | 0.26x | CN¥541.58 Million | CN¥2.07 Billion | ▼ -42.5% |
| 2013 | 0.46x | CN¥577.24 Million | CN¥1.27 Billion | ▲ +15.6% |
| 2012 | 0.39x | CN¥288.01 Million | CN¥731.33 Million | ▼ -5.7% |
| 2011 | 0.42x | CN¥277.83 Million | CN¥665.51 Million | ▲ +148.6% |
| 2010 | 0.17x | CN¥115.66 Million | CN¥688.82 Million | ▼ -7.7% |
| 2009 | 0.18x | CN¥103.88 Million | CN¥571.26 Million | ▼ -40.4% |
| 2008 | 0.30x | CN¥189.26 Million | CN¥620.62 Million | ▲ +1458.1% |
| 2007 | 0.02x | CN¥11.94 Million | CN¥610.24 Million | ▼ -88.5% |
| 2006 | 0.17x | CN¥95.77 Million | CN¥562.27 Million | ▲ +539.5% |
| 2005 | 0.03x | CN¥17.38 Million | CN¥652.65 Million | ▲ +121.5% |
| 2004 | -0.12x | CN¥-44.80 Million | CN¥361.10 Million | ▼ -137.0% |
| 2003 | 0.34x | CN¥92.10 Million | CN¥274.93 Million | ▼ -20.3% |
| 2002 | 0.42x | CN¥73.46 Million | CN¥174.87 Million | — |